Drug Treatment Study for Patients with Triple Negative Breast Cancer
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery.
In order to participate you must meet the following criteria:
- Have a diagnosis of invasive adenocarcinoma of the breast that has been made by core needle biopsy.
- Are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
You will be excluded from the study if any of the following criteria apply to you:
- Have had an excisional biopsy or lumpectomy performed prior to study entry or have clinical or radiologic evidence of metastatic disease.
- Have had treatment including radiation therapy, chemotherapy, or targeted therapy, for the currently diagnosed breast cancer prior to randomization.
This is a partial list of inclusion and exclusion criteria.